Iovance Biotherapeutics is trading 4.24% up at $8.96, continuing recent strength after gaining 5.65% on September 11, 2026.
- Management highlighted stronger Amtagvi demand, improving margins, and expanded treatment-center capacity.
- Available coverage does not explicitly establish those developments as the cause of the September 14 move.
- The broader market is lower, and no new major announcement was identified.